Delivery Systems Developed for Treatment Combinations to Improve Adoptive Cell Therapy
Advanced Materials · 2024-10 · 36 (40)
DOI: 10.1002/adma.202407525 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Materials, online erschienen am 20.08.2024. Verfasst von Fengfei Xu und 8 weiteren Autor:innen. Beteiligte Einrichtung: CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience …. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 201 Literaturangaben. Gefördert von: National Key Research & Development Program of China, NSFC key project, NSFC international collaboration key project.
Abstract (Originalsprache)
Adoptive cell therapy (ACT) has shown great success in the clinic for treating hematologic malignancies. However, solid tumor treatment with ACT monotherapy is still challenging, owing to insufficient expansion and rapid exhaustion of adoptive cells, tumor antigen downregulation/loss, and dense tumor extracellular matrix. Delivery strategies for combination cell therapy have great potential to overcome these hurdles. The delivery of vaccines, immune checkpoint inhibitors, cytokines, chemotherapeutics, and photothermal reagents in combination with adoptive cells, have been shown to improve the expansion/activation, decrease exhaustion, and promote the penetration of adoptive cells in solid tumors. Moreover, the delivery of nucleic acids to engineer immune cells directly in vivo holds promise to overcome many of the hurdles associated with the complex ex vivo cell engineering strategies. Here, these research advance, as well as the opportunities and challenges for integrating delivery technologies into cell therapy s are discussed, and the outlook for these emerging areas are criticlly analyzed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing, 100190, P.R. China.
- University of Chinese Academy of Sciences, Beijing, 100049, P. R. China.
- Department of Chemistry, Center for BioAnalytical Chemistry, Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology, New Cornerstone Science Institute, Tsinghua University, Beijing, China.
- Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, China.
- College of Chemistry & Materials Science, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of Ministry of Education, State Key Laboratory of New Pharmaceutical Preparations and Excipients, Chemical Biology…
- College of Biomedical Engineering, Guangzhou Medical University, Guangzhou, 510260, China.
ORCID-Profile: Xing-Jie Liang
Förderung
- National Key Research & Development Program of China
- NSFC key project
- NSFC international collaboration key project
- Chinese Academy of Sciences (CAS-NSTDA) International Partnership Program
- Science Fund for Creative Research Groups of Nature Science Foundation of Hebei Province
Zitieren
APA
Xu, F., Ni, Q., Gong, N., Xia, B., Zhang, J., Guo, W., Hu, Z., Li, J., & Liang, X. J. (2024). Delivery Systems Developed for Treatment Combinations to Improve Adoptive Cell Therapy. Advanced Materials, 36(40). https://doi.org/10.1002/adma.202407525
Vancouver
Xu F, Ni Q, Gong N, Xia B, Zhang J, Guo W, et al. Delivery Systems Developed for Treatment Combinations to Improve Adoptive Cell Therapy. Advanced Materials. 2024;36(40). doi:10.1002/adma.202407525
BibTeX
@article{Xu2024,
author = {Xu, Fengfei and Ni, Qiankun and Gong, Ningqiang and Xia, Bozhang and Zhang, Jinchao and Guo, Weisheng and Hu, Zhongbo and Li, Jinghong and Liang, Xing-Jie},
title = {Delivery Systems Developed for Treatment Combinations to Improve Adoptive Cell Therapy},
journal = {Advanced Materials},
year = {2024},
volume = {36},
number = {40},
doi = {10.1002/adma.202407525}
}
EUVIMED